The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001369314p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
16/09/2026
Date registered
Help: Date registered
16/11/2026
Date last updated
Help: Date last updated
16/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/11/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title

Integration of ultrasound to assess progress in labour: a randomised controlled trial.
The primary objective of this study is to demonstrate that the use of ultrasound to monitor progress in labour will reduce the rate of intrapartum pyrexia amongst nulliparous singleton women undergoing IOL at term.
Scientific title
The effect of labour progress assessment via integrated ultrasound on the rate of intrapartum pyrexia among nulliparous singleton women undergoing labour induction at term.
Additional trial identifiers [1] 318434 0
Nil
Universal Trial Number (UTN)
Trial acronym
LABORUS
Related trial records

Health condition
Health condition(s) studied:
pregnancy 343600 0
childbirth complications 343603 0
Condition category
Condition code
Reproductive Health and Childbirth 339701 339701 0 0
Fetal medicine and complications of pregnancy
Reproductive Health and Childbirth 339893 339893 0 0
Childbirth and postnatal care
Reproductive Health and Childbirth 339894 339894 0 0
Other reproductive health and childbirth disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Pregnant women who have been scheduled for an induction of labour (IOL) will be invited to take part in this trial at the hospital. After obtaining informed written consent, participants will be randomly assigned to one of two arms: the progress of their labour will be assessed with digital vaginal examinations as per standard care, or labour progress will be assessed using ultrasound.
The device used will be a GE Voluson Swift or Voluson S8 ultrasound machine with a wide-band convex transducer. Standard non-invasive ultrasound gel and probe covers will be used in conjunction with the ultrasound machine. Participating women will be in a supine position and will be asked to flex and abduct their hips to allow transducer access.
Participants allocated to the ultrasound arm will still undergo a digital vaginal examination immediately prior to induction to assess the cervix. If required for specific procedures for the method of IOL or for specialised fetal interventions or for intrapartum clinical indications, digital vaginal examinations will still be performed.
Before the artificial rupture of the membrane (ARM)m Healthcare practitioners with extensive experience in ultrasound will perform a baseline scan assessing fetal biometry, Doppler parameters, amniotic fluid, and cervical length, followed by serial transabdominal and transperineal ultrasound assessments to monitor labor progress. These intrapartum scans are conducted every 12 hours prior to regular contractions or oxytocin initiation, increasing to every 4 hours during the latent phase of active labor, and every 2 hours during the active phase. Monitoring continues until sonographic cervical dilatation (SCD) reaches 10 cm or can no longer be visualized.

Throughout the trial, participants undergo systematic evaluations and data collection before, during, and after labor. Real-time pain and anxiety levels are assessed using physical acrylic Visual Analogue Scale (VAS) sliders and State-Trait Anxiety Inventory (STAI) forms prior to and immediately following each examination. Within 72 hours of delivery, participants complete the Client Satisfaction Questionnaire (CSQ-8) and the Satisfaction with Examinations in Labor Questionnaire to evaluate their overall birth experience. Immediately following birth, clinical data—including neonatal birthweight, Apgar scores, umbilical cord arterial pH, and placental pathology or swabs in cases of suspected infection—are recorded. Finally, a two-week post-delivery follow-up phone call is conducted to re-evaluate patient satisfaction and identify any readmissions, postpartum fever, or endometritis.
Every scheduled intrapartum ultrasound scan and digital vaginal examination (VE) is recorded in an electronic Case Record Form (eCRF) in REDCap. The system logs the exact timing, frequency, indication, and specific ultrasound measurements (e.g., parasagittal angle of progression (psAOP), head perineum distance (HPD), SCD) for each session, allowing real-time tracking of whether scans occur according to the protocol-mandated intervals.
Intervention code [1] 335336 0
Diagnosis / Prognosis
Intervention code [2] 335337 0
Treatment: Devices
Description of the comparator or control
Women allocated to the control group will undergo digital vaginal examinations from ARM onwards until caesarean section or operative vaginal delivery by experienced healthcare practitioners at the hospital. Based on standard clinical practice the VEs will be conducted every 4 hours during the latent phase and active labour or whenever clinically indicated to check cervical dilatation and fetal head position until the baby is delivered.
Control group
Active

Outcomes
Primary outcome [1] 346875 0
Rate of pyrexia during IOL in singleton pregnancies when compared to current standard of care.
Timepoint [1] 346875 0
Intrapartum, from the moment of the artificial rupture of the membrane throughout the course of labour during the induction process until the baby is delivered.
Secondary outcome [1] 467985 0
Readmissions
Timepoint [1] 467985 0
Two weeks after delivery
Secondary outcome [2] 467986 0
Baby's APGAR score
Timepoint [2] 467986 0
at 5 minutes and at 10 minutes after delivery
Secondary outcome [3] 467987 0
NICU admissions
Timepoint [3] 467987 0
Postpartum during the hospital stay up to discharge
Secondary outcome [4] 469391 0
Maternal pain level during assessment of progress in labour
Timepoint [4] 469391 0
Evaluated immediately post-examination (after each vaginal examination or ultrasound assessment)
Secondary outcome [5] 469392 0
Maternal overall satisfaction with labor examinations and birth experience
Timepoint [5] 469392 0
Administered twice: - Within 72 hours post-delivery (prior to discharge) - During a 2-week post-delivery follow-up phone call
Secondary outcome [6] 469393 0
Maternal anxiety associated with labour monitoring
Timepoint [6] 469393 0
Administered immediately before and after each examination (digital vaginal examination or ultrasound scan) during labour
Secondary outcome [7] 469394 0
Neonatal Infection or Sepsis
Timepoint [7] 469394 0
Monitored during the initial hospital stay and evaluated up to the 2-week follow-up call
Secondary outcome [8] 469600 0
Endometritis
Timepoint [8] 469600 0
Two week post-delivery follow-up phone call

Eligibility
Key inclusion criteria
Nulliparous women with a singleton pregnancy and gestation >37 weeks due to undergoing IOL.
Cephalic presentation and intact membrane.
Informed consent provided.
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Healthy volunteers
No
Key exclusion criteria
Women younger than 18 years
Women pregnant with a breech presentation
Women who are unconscious or severely ill
Women with learning difficulties or serious mental illness

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer-generated random sequence
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
A previous study showed a reduction of 60% in pyrexia in labour among women undergoing ultrasound to monitor progress in labour. Anticipating that intrapartum ultrasound would reduce the relative rate of the primary objective by 45% or greater (conservatory approach), equivalent to a rate of 11%, it was estimated that 506 participants would be needed in total for an 80% power, a confidence level of 95%, at an allocation ratio of 1:1 (standard of care: ultrasound), assuming a post randomisation loss to follow-up/withdraw rate of 15%, recruitment of 595 participants will be needed, approximating to a 600 participants sample size.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 30218 0
Monash Medical Centre - Clayton campus - Clayton
Recruitment postcode(s) [1] 46612 0
3168 - Clayton
Recruitment outside Australia
Country [1] 28543 0
Spain
State/province [1] 28543 0
Madrid
Country [2] 28544 0
Hong Kong
State/province [2] 28544 0
Shatin District, New Territories
Country [3] 28545 0
France
State/province [3] 28545 0
Paris
Country [4] 28546 0
Italy
State/province [4] 28546 0
Parma
Country [5] 28547 0
Switzerland
State/province [5] 28547 0
Basel

Funding & Sponsors
Funding source category [1] 323035 0
Other Collaborative groups
Name [1] 323035 0
Hospital Universitario de Torrejon
Country [1] 323035 0
Spain
Primary sponsor type
Individual
Name
Dr Pongsarat Sukjit - Monash Health
Address
Country
Australia
Secondary sponsor category [1] 325952 0
Individual
Name [1] 325952 0
Prof. Daniel Rolnik - Monash Health
Address [1] 325952 0
Country [1] 325952 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 321422 0
Monash Health Human Research Ethics Committee A
Ethics committee address [1] 321422 0
Ethics committee country [1] 321422 0
Australia
Date submitted for ethics approval [1] 321422 0
16/09/2026
Approval date [1] 321422 0
Ethics approval number [1] 321422 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153670 0
Dr Pongsarat Sukjit
Address 153670 0
Monash Health, 246 Clayton Road, Clayton VIC 3168
Country 153670 0
Australia
Phone 153670 0
+61 452 644 239
Fax 153670 0
Email 153670 0
Contact person for public queries
Name 153671 0
Pongsarat Sukjit
Address 153671 0
Monash Health, 246 Clayton Road, Clayton VIC 3168
Country 153671 0
Australia
Phone 153671 0
+61 3 9594 6666
Fax 153671 0
Email 153671 0
Contact person for scientific queries
Name 153672 0
Pongsarat Sukjit
Address 153672 0
Monash Health, 246 Clayton Road, Clayton VIC 3168
Country 153672 0
Australia
Phone 153672 0
+61 3 9594 6666
Fax 153672 0
Email 153672 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Published results
• Primary outcome(s)
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Health economic analyses
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.